These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

593 related items for PubMed ID: 17163237

  • 1. Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.
    Reid DM, Hosking D, Kendler D, Brandi ML, Wark JD, Weryha G, Marques-Neto JF, Gaines KA, Verbruggen N, Melton ME.
    Clin Drug Investig; 2006; 26(2):63-74. PubMed ID: 17163237
    [Abstract] [Full Text] [Related]

  • 2. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study.
    Hosking D, Adami S, Felsenberg D, Andia JC, Välimäki M, Benhamou L, Reginster JY, Yacik C, Rybak-Feglin A, Petruschke RA, Zaru L, Santora AC.
    Curr Med Res Opin; 2003; 19(5):383-94. PubMed ID: 13678475
    [Abstract] [Full Text] [Related]

  • 3. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
    Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE, Fosamax Actonel Comparison Trial Investigators.
    J Bone Miner Res; 2005 Jan; 20(1):141-51. PubMed ID: 15619680
    [Abstract] [Full Text] [Related]

  • 4. Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis.
    Sebba AI, Bonnick SL, Kagan R, Thompson DE, Skalky CS, Chen E, de Papp AE, Fosamax Actonel Comparison Trial investigators.
    Curr Med Res Opin; 2004 Dec; 20(12):2031-41. PubMed ID: 15706659
    [Abstract] [Full Text] [Related]

  • 5. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years.
    Bonnick S, Saag KG, Kiel DP, McClung M, Hochberg M, Burnett SM, Sebba A, Kagan R, Chen E, Thompson DE, de Papp AE.
    J Clin Endocrinol Metab; 2006 Jul; 91(7):2631-7. PubMed ID: 16636120
    [Abstract] [Full Text] [Related]

  • 6. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
    Reid DM, Hosking D, Kendler D, Brandi ML, Wark JD, Marques-Neto JF, Weryha G, Verbruggen N, Hustad CM, Mahlis EM, Melton ME.
    Int J Clin Pract; 2008 Apr; 62(4):575-84. PubMed ID: 18324951
    [Abstract] [Full Text] [Related]

  • 7. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International.
    Sambrook PN, Geusens P, Ribot C, Solimano JA, Ferrer-Barriendos J, Gaines K, Verbruggen N, Melton ME.
    J Intern Med; 2004 Apr; 255(4):503-11. PubMed ID: 15049885
    [Abstract] [Full Text] [Related]

  • 8. Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.
    Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M, Snorre Øfjord E.
    Clin Ther; 2007 Sep; 29(9):1937-49. PubMed ID: 18035193
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S.
    Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
    [Abstract] [Full Text] [Related]

  • 10. Response to oral bisphosphonates in subgroups of younger and older postmenopausal women.
    Stovall DW, Beard MK, Barbier S, Chen E, Rosenberg E, de Papp AE.
    J Womens Health (Larchmt); 2010 Mar; 19(3):491-7. PubMed ID: 20141367
    [Abstract] [Full Text] [Related]

  • 11. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
    Roux C, Hofbauer LC, Ho PR, Wark JD, Zillikens MC, Fahrleitner-Pammer A, Hawkins F, Micaelo M, Minisola S, Papaioannou N, Stone M, Ferreira I, Siddhanti S, Wagman RB, Brown JP.
    Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
    [Abstract] [Full Text] [Related]

  • 12. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
    Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora AC, Kaur A, Thompson DE, Yates J, Orloff JJ.
    Aging (Milano); 2000 Feb; 12(1):1-12. PubMed ID: 10746426
    [Abstract] [Full Text] [Related]

  • 13. The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo-controlled study.
    Leung JY, Ho AY, Ip TP, Lee G, Kung AW.
    Bone; 2005 Feb; 36(2):358-64. PubMed ID: 15780963
    [Abstract] [Full Text] [Related]

  • 14. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ, MK-677/Alendronate Study Group.
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [Abstract] [Full Text] [Related]

  • 15. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
    Bonnick S, De Villiers T, Odio A, Palacios S, Chapurlat R, DaSilva C, Scott BB, Le Bailly De Tilleghem C, Leung AT, Gurner D.
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4727-35. PubMed ID: 24064689
    [Abstract] [Full Text] [Related]

  • 16. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.
    Ringe JD, Möller G.
    Rheumatol Int; 2009 Dec; 30(2):213-21. PubMed ID: 19430791
    [Abstract] [Full Text] [Related]

  • 17. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study.
    Miller PD, Epstein S, Sedarati F, Reginster JY.
    Curr Med Res Opin; 2008 Jan; 24(1):207-13. PubMed ID: 18042311
    [Abstract] [Full Text] [Related]

  • 18. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [Abstract] [Full Text] [Related]

  • 19. The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis.
    Yan Y, Wang W, Zhu H, Li M, Liu J, Luo B, Xie H, Zhang G, Li F.
    J Bone Miner Metab; 2009 Jan; 27(4):471-8. PubMed ID: 19343272
    [Abstract] [Full Text] [Related]

  • 20. Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
    Sarioglu M, Tuzun C, Unlu Z, Tikiz C, Taneli F, Uyanik BS.
    Rheumatol Int; 2006 Jan; 26(3):195-200. PubMed ID: 15580349
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.